BIO-TECHNE Corp Contract Liability (Deferred Revenue)
BIO-TECHNE Corp (TECH) had Contract Liability (Deferred Revenue) of $36.07 million as of 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-24
- 2026-06-30: Contract with Customer, Liability, Current $36.07M.
- 2026-03-31: Contract with Customer, Liability, Current $38.43M.
- 2025-12-31: Contract with Customer, Liability, Current $31.03M.
- 2025-09-30: Contract with Customer, Liability, Current $30.45M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $36.07M 10-K · filed 2026-08-24 |
| 2026-03-31 | $38.43M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $31.03M 10-Q · filed 2026-02-04 |
| 2025-09-30 | $30.45M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $32.57M 10-K · filed 2026-08-24 |
| 2025-03-31 | $32.27M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $27.71M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $26.61M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $27.93M 10-K · filed 2025-08-22 |
| 2024-03-31 | $30.11M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $28.43M 10-Q · filed 2024-02-07 |
| 2023-09-30 | $24.52M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $23.07M 10-K · filed 2024-08-22 |
| 2023-03-31 | $24.88M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $21.81M 10-Q · filed 2023-02-07 |
| 2022-09-30 | $22.06M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $23.41M 10-K · filed 2023-08-23 |
| 2022-03-31 | $23.11M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $19.08M 10-Q · filed 2022-02-07 |
| 2021-09-30 | $19.12M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $19.00M 10-K · filed 2022-08-24 |
| 2021-03-31 | $18.71M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $13.22M 10-Q · filed 2021-02-08 |
| 2020-09-30 | $13.29M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $13.05M 10-K · filed 2021-08-25 |
| 2020-03-31 | $13.56M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $11.89M 10-Q · filed 2020-02-06 |
| 2019-09-30 | $9.11M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $9.08M 10-K · filed 2020-08-26 |
| 2019-03-31 | $10.11M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $8.40M 10-Q · filed 2019-02-07 |
| 2018-09-30 | $8.76M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $8.11M 10-K/A · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |